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SRC-3/AIB1 is an important growth coactivator
whose activity should be tightly regulated since
excess activation results in oncogenesis.
Herein, we provide evidence that coordinated
phosphorylation-dependent ubiquitination reg-
ulates SRC-3 coactivator activation and tran-
scriptional specificity. We discovered a critical
‘‘actron/degron’’ element in SRC-3 that is re-
quired for this phosphorylation-dependent
ubiquitination event and identified GSK3 and
SCFFbw7a as the respective responsible kinase
and E3 ubiquitin ligase. Interestingly, despite
that SCFFbw7a enhances ubiquitination and pro-
motes eventual transcription-coupled degrada-
tion of SRC-3 in a phosphorylation- and Fbw7a
dosage-dependent manner, our results also un-
covered a nonproteolytic ‘‘activation’’ code for
SRC-3 ubiquitination induced by Fbw7a. We
propose that ubiquitination of SRC-3 is a phos-
pho-mediated biphasic event and that a transi-
tion from multi-(mono)ubiquitination (SRC-3
activation) to long-chain polyubiquitination
(SRC-3 degradation) is processive during the
transcriptional coactivation of select transcrip-
tion factors and can serve as a ‘‘transcriptional
time clock’’ to control both the activation and
the functional lifetime of coactivators.
INTRODUCTION
The gene for SRC-3 (also known as AIB1, ACTR, p/CIP,
TRAM-1, and RAC3) was reported to be amplified
in5%–10% of human breast tumors and overexpressed
in 60% of tumors, suggesting that SRC-3 provides
a growth advantage for breast cancer cells (Anzick et al.,
1997). SRC-3 is a bona fide oncogene and plays a role in
initiation and progression of mammary gland tumorigene-
sis (Kuang et al., 2004; Torres-Arzayus et al., 2004). The
transcriptional coactivation activity of SRC-3 is subject toregulation by posttranslational modifications such as
phosphorylation (Font de Mora and Brown, 2000; Wu
et al., 2002, 2004). Phosphorylation of SRC-3 was recently
demonstrated to be important for coactivation of select
steroid receptors and was linked to its proliferative/onco-
genic potential (Wu et al., 2004). Although themechanisms
underpinning normal regulation of cellular SRC-3 levels are
not completely known, the process appears to be complex
and to involve both ubiquitin-dependent and -independent
proteasome pathways (Li et al., 2006; Lonard et al., 2004).
Ubiquitination plays a major role in the regulation of cel-
lular processes, and the best-studied function of ubiquiti-
nation is its role in protein degradation (Varshavsky, 2005).
Among the E3 ubiquitin ligases, the SCF complexes are
a well-studied class of E3s; the F box protein subunit of
SCF directly binds to substrates and often confers sub-
strate specificity (Elledge and Harper, 1998). Of the iden-
tified F box proteins, Skp2 and Fbw7 (hCdc4, Sel10,
hAgo) are known to control the levels of several key regu-
latory proteins in the cell cycle (Bornstein et al., 2003;
Kamura et al., 2003; Moberg et al., 2001).
Although cellular signaling and SRC-3 protein turnover
both affect the physiological functions and activity of
SRC-3, it was unclear as to whether signaling regulates
the cellular levels/turnover of SRC-3 and how, in turn, it
may impact SRC-3 transcriptional function. In the current
report, we show that cellular signaling regulates both tran-
scriptional activation and turnover of SRC-3 through a
coupled phosphorylation-dependent ubiquitination code.
We demonstrate that phosphorylation of a critical peptide
element (actron/degron) surrounding S505 is required for
the subsequent ubiquitination of SRC-3 and we further
identify GSK3 and SCFFbw7a as the responsible kinase
and E3 ligase, respectively. Our results advance our un-
derstanding of SRC-3 degradation but, importantly, un-
cover a nonproteolytic ‘‘activation’’ function for SRC-3
ubiquitination. We found that phosphorylation-dependent
multi-(mono)ubiquitination promotes SRC-3 transcription
factor specificity and coactivator function. We propose
that select cellular signals regulate SRC-3 transcriptional
activation and turnover by the means of a ‘‘phosphoryla-
tion-dependent ubiquitination code.’’ In this manner,
transcription- and phospho-dependent ubiquitination of
SRC-3 acts as a ‘‘time clock’’ for its functional lifetime.Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc. 1125
Figure 1. GSK3 Phosphorylates SRC-3
on S505
(A) An Akt/PB expression construct that con-
tains the myristoylation signal was transfected
into the MCF-7 cells to stably express this con-
stitutively active Akt/PKB (CA-Akt). The ex-
pression of the CA-Akt was confirmed by west-
ern blotting, and the consequence of CA-Akt
expression was verified by the increased phos-
phorylation of its direct target, GSK3, with anti-
pS21/S9 of GSK3a/b. n.s., nonspecific.
(B) The effects of CA-Akt expression on the
phosphorylation status of SRC-3 were deter-
mined by the western blotting with each of
the phospho-specific antibodies as previously
described (Wu et al., 2004). The numbers
reflected the ratio of the values of phosphory-
lated SRC-3/total SRC-3 between the
CA-Akt-expressing cells and the control cells
(pCR3.1), which was set at 1 for each panel.
Shown is a representative western blotting re-
sult from two independent experiments with
similar results.
(C) Sequence analysis revealed a perfect GSK3
consensus phosphorylation site in SRC-3.
Arrows indicated possible priming phosphory-
lation sites.
(D) The phosphorylation of S505 on the indi-
cated SRC-3 was determined by western blot-
ting with anti-phospho-S505 as described in
(A). The priming phosphorylation site for phos-
phorylation of S505 by GSK3 was determined
to be S509.
(E) A summary of the proposed signaling
events, comprised of Akt/PKB and GSK3 that
regulate S505 phosphorylation on SRC-3.
All Quantification was performed by the NIH
Image program.RESULTS
SRC-3 Is a Genuine Substrate of the Akt/PKB-GSK3
Signaling Pathway
Since the Akt/PKB signaling pathway is activated in many
types of cancers (Brazil et al., 2004) and SRC-3/AIB1 has
been shown to be a bona fide oncogene, we investigated
the existence of crosstalk between Akt/PKB and SRC-3
signaling. We stably expressed a constitutively active
form of Akt/PKB (CA-Akt) in MCF-7 breast cancer cells
and determined the effects of Akt/PKB activation on the
phosphorylation of SRC-3. Expression of the constitutive
Akt/PKB was detected by western blotting with anti-HA,
and expression of the constitutive Akt/PKB resulted in
increased phosphorylation of its downstream target, gly-
cogen synthase kinase-3 (GSK3), as revealed by western
blotting using phospho-specific antibodies against GSK3
(Figure 1A).
Since the phosphorylation status of SRC-3 was shown
to be important for its function, we determined the effects
of CA-Akt/PKB expression on the phosphorylation of
SRC-3 (Wu et al., 2004). Among six known phosphoryla-1126 Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc.tion sites (pT24, pS505, pS543, pS857, pS860, and
pS867), phosphorylation on S505 was found to be signif-
icantly reduced (70%) upon expression of CA-Akt. Given
that expression of CA-Akt reduced phosphorylation of
S505 (Figure 1B), it suggested that S505 may be phos-
phorylated by a kinase whose activity is inhibited by Akt/
PKB. To identify this Akt/PKB-regulated kinase, we fo-
cused on GSK3 for the following reasons. The activity of
GSK3 is known to be inhibited by Akt/PKB through phos-
phorylation on critical residues (Cohen, 1999), and expres-
sion of CA-Akt resulted in increased phosphorylation of
GSK3 in MCF-7 (Figure 1A). GSK3 is one of the kinases
that we previously showed to phosphorylate SRC-3 on
S505 in vitro (Wu et al., 2004), and sequence analysis re-
vealed S505 to be a perfect GSK3 consensus phosphory-
lation site (Figure 1C).
For GSK3 to phosphorylate a substrate protein, it often
requires a priming phosphorylation, i.e., prior phosphory-
lation of an amino acid sequence of four amino acids
C-terminal (+4) to the GSK3 target site (0) (Figure 1C). We
noted that, in addition to S509, three additional potential
priming sites for GSK are present (T513, S517, and
S521) that could initiate this phosphorylation event. We
mutated each of these potential phosphorylatable amino
acids to alanines and determined whichmutation interrup-
ted the phosphorylation of S505. Our results showed that
phosphorylation of S505 was not affected by mutations of
T513, S517, or S521 (Figure 1Di). In contrast, phosphory-
lation of S505 was abolished when S509 was mutated to
alanine (Figure 1Dii). As controls for the phospho-specific
antibody, mutation of S505 to alanine (S505A) or glutamic
acid (S505E) prevented the detection of SRC-3 by the
antibody. Thus, phosphorylation of S505 requires a prim-
ing phosphorylation at S509, and we identified SRC-3 to
be a likely GSK3 substrate.
Phosphorylation of S505 Regulates SRC-3
Protein Turnover
As shown in Figure 1B, we consistently observed an in-
creased level of SRC-3 when cells expressed CA-Akt,
suggesting that inhibition of S505 phosphorylation in-
creases the stability of SRC-3. We first used a pharmaco-
logical agent, LiCl, to inhibit GSK3 activity (Klein and Mel-
ton, 1996). Consistent with an earlier report (Lonard et al.,
2004), the half-life of endogenous SRC-3 in MCF-7 cells
that did not receive LiCl treatment was determined to
be3–4 hr (Figures 2A and 2B). In contrast, LiCl treatment
dramatically stabilized SRC-3 in MCF-7 cells, and no sig-
nificant reduction of SRC-3 protein was evident in the
presence of cycloheximide after 10 hr (Figures 2A and
2B). Accordingly, phosphorylation of S505 sampled at
the 10 hr point was found to be abolished in cells treated
with LiCl (Figure 2B, inset), suggesting that phosphoryla-
tion of S505 by GSK3 correlates with SRC-3 stability.
We compared the half-life of wild-type SRC-3 with
SRC-3 carrying S505 mutated to alanine (S505A). Wild-
type SRC-3 transiently expressed in HEK293 cells exhibits
a half-life (4 hr) similar to its endogenous counterpart
from MCF-7 cells, while the SRC-3 (S505A) mutant dis-
played a much longer half-life (Figure 2D). A control
SRC-3 mutant (T24A) showed a similar half-life to the
wild-type SRC-3.
GSK3 Regulates Phosphorylation and Functional
Levels of SRC-3
Knockdown of GSK3a (Figure 3Ai) or GSK3b (Figure 3Aii)
by siRNA in MCF-7 cells resulted in elevated cellular
SRC-3 levels as compared to control. Increased SRC-3
protein is a result of increased half-life as evidenced by
the knockdown of GSK3 (Figure 3Aiii). In addition, expres-
sion of either GSK3a or GSK3b enhanced SRC-3 phos-
phorylation at S505 (Figure 3B). These results are in line
with data from Figure 2 and indicate that GSK3 promotes
SRC-3 turnover in an S505 phosphorylation-dependent
fashion. Sequence comparison revealed that SRC-3 con-
tains a degradation motif similar to that found in several
other important cellular growth-regulatory proteins (Fig-
ure 3C) (Doble and Woodgett, 2003; Oberg et al., 2001;
Wei et al., 2005; Welcker et al., 2004).Figure 2. Phosphorylation of S505 Is Important for SRC-3
Stability
(A) The effects of LiCl, a specific inhibitor of GSK3 kinase activity, on
the half-life of endogenous SRC-3 from MCF-7 cells were determined.
MCF-7 cells pretreated or not with LiCl (10 mM) for 2 hr were subse-
quently treated with cycloheximide (20 mg/ml), and samples were col-
lected at the indicated times after addition of cycloheximide to deter-
mine the SRC-3 levels. Shown is a representative western blotting
results from two independent cycloheximide chase experiments with
similar results. The inset shows that S505 phosphorylation is reduced
from samples collected from a parallel experiment that were treated or
not with LiCl for 10 hr.
(B) Graphic representation of the western blotting results in (A). The in-
tensity at the beginning of cycloheximide treatment (time 0) is set as
1 for each group. Each point represents the average of the relative in-
tensity to the starting point from two independent experiments.
(C) HEK293 cells were transfected with the indicated Flag-SRC-3 ex-
pression constructs, and samples were collected after cycloheximide
(20 mg/ml) treatment at the indicated time to determine the Flag-SRC-3
levels.
(D) Graphic representation of the western blotting results in (C).Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc. 1127
Figure 3. GSK3 Regulates the Half-Life and Cellular Levels of SRC-3
(A) MCF-7 cells were transfected with siRNAs specific for either GSK3a (Ai), GSK3b (Aii), or GSK3a and GSK3b combined (Aiii). The effects of knock-
down of GSK3 on the levels and half-life of SRC-3 were determined by western blotting with anti-SRC-3. The b-actin served as a protein loading
control.
(B) Flag-SRC-3 was cotransfected with either GSK3a or GSK3b into HEK293 cells to determine the effects of GSK3 expression on phosphorylation of
S505. Phosphorylation of S505 was determined by western blotting with anti-phospho-S505. The immunoprecipitated Flag-SRC-3 and the expres-
sion of GSK3a and GSK3b were shown.
(C) Sequence alignment of several phosphodegron-containing proteins.
(Di) All the following experiments to examine the ubiquitination of SRC-3 in cells were performed essentially as described in Experimental Procedures.
Briefly, protein extracts from HEK293 cells cotransfected with Flag-SRC-3, HA-ubiquitin, and with or without Myc-GSK3b were immunoprecipitated
with anti-Flag. The possible ubiquitination of Flag-SRC-3 from the immunoprecipitates was examined by western blotting with anti-Flag. (Dii) As in (Di)
except a kinase-defective GSK3b was used.
(E) Protein extracts and total RNA from MCF-7 cells treated with EGF (100 ng/ml) or insulin (1 mM) alone or in combination with the indicated kinase
inhibitors (25 mM each) were analyzed by the indicated antibodies or RT-PCR.We next demonstrated that GSK3b augmented SRC-3
ubiquitination (Figure 3Di). The kinase activity of GSK3b
was required since kinase-defective GSK3b did not en-1128 Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc.hance SRC-3 ubiquitination (Figure 3Dii). Stimulation of
resting cells with physiological stimuli, such as EGF and
insulin, resulted in inhibition of GSK3 activity and elevated
levels of SRC-3 (Figure 3E, fourth and first panels, lanes
1–3). The elevated levels of SRC-3 were associated with
decreased S505 phosphoryation and SRC-3 ubiquitina-
tion (Figure 3E, second and third panels, lanes 1–3). The
effects of EGF and insulin were not at the transcriptional
levels, as SRC-3 mRNA was not affected and pretreat-
ment with proper kinase inhibitors abolished the effects.
Our results indicate that phosphorylation of S505 by
GSK3 targets SRC-3 for degradation by a phosphoryla-
tion-dependent ubiquitin-proteasome pathway.
SCFFbw7a Is an SRC-3-Specific E3 Ligase that
Regulates SRC-3 Ubiquitination and Nuclear
Turnover in a Phosphorylation-Dependent Manner
To demonstrate that S505 phosphorylation is directly in-
volved in SRC-3 ubiquitination, we examined the extent
of ubiquitination observed for SRC-3 phosphorylation mu-
tants. Our results showed that mutation of S505 to alanine
(S505A) decreased the extent of SRC-3 ubiquitination,
and substitution of glutamic acid at S505 (S505E) signifi-
cantly increased SRC-3 ubiquitination when compared
to the wild-type SRC-3 (Figure 4A, top panel, compare
lanes 2–4).
Since ubiquitin E3 ligases are most responsible for de-
termining substrate specificity (Hershko and Ciechanover,
1998; Varshavsky, 1997) and the sequences surrounding
S505 are similar to those proteins whose abundance is
regulated by Fbw7 (hCdc4, sel10, hAgo) (Figure 3C)
(Koepp et al., 2001; Moberg et al., 2001; Oberg et al.,
2001), we examinedwhether Fbw7 plays a role in the ubiq-
uitination of SRC-3. Among the three isoforms of Fbw7
(Fbw7a, Fbw7b, and Fbw7g), only Fbw7a coimmunopre-
cipitated with wild-type SRC-3 (data not shown;
Figure 4A, third panel from top, lane 2); the amount of
Fbw7a coimmunoprecipitated with S505A was less than
that obtained fromwild-type SRC-3 (Figure 4A, third panel
from top, lane 3). In contrast, the amount of Fbw7a found
associated with S505Ewas substantially more than that of
wild-type SRC-3 (Figure 4A, third panel from top, lane 4),
and Fbw1a and Fbw1b (b-TrCP) were not detected
(Figure 4A, fourth panel from top and data not shown).
Our results suggested that Fbw7a is an E3 ligase that
might specifically control SRC-3 cellular turnover through
phosphorylation-dependent ubiquitination. In support,
our data further revealed that siRNA knockdown of
Fbw7 (particularly Fbw7a) resulted in elevated levels of
SRC-3 (50%) in MCF-7 cells (Figure 4Bi). Conversely,
overexpression of Fbw7a markedly decreased the half-
life of SRC-3 (Figure 4Bii).
Figure 4Ci shows that phosphorylation of S505 byGSK3
(middle panel, lanes 1 and 2) enhanced the binding of
Fbw7a to SRC-3 (top panel, lanes 1 and 2); mutation of
S505 to alanine (S505A) prevented phosphorylation by
GSK3 (middle panel, lanes 3 and 4) and abolished the en-
hancement in binding (top panel, lanes 3 and 4). We next
showed that expression of Fbw7a efficiently decreased
the levels of the wild-type SRC-3 in a dosage-dependent
manner (Figure 4Cii, lanes 1–3). The effect of Fbw7a onSRC-3 levels at a lower dosage (SRC-3: Fbw7a = 1:5)
was attenuated when S505 was mutated to alanine
(S505A) (compare lanes 2 and 5), but not at a higher dos-
age (SRC-3: Fbw7a = 1:25, lanes 3 and 6). The effect of
Fbw7a on SRC-3 levels was completely abolished even
at a higher dosage of Fbw7a (SRC-3: Fbw7a = 1:25)
when the priming phosphorylation site S509 was mutated
to alanine (S509A) (lanes 7–9). As expected, no effects
were observed when both S505 and S509 were mutated
to alanines (S505/509A) (lanes 10–12). Taken together,
our results identify a critical degron signaling element in
SRC-3 and demonstrate that phosphorylations of both
S505 and S509 within this element are important for
Fbw7a to regulate SRC-3 turnover. We next investigated
whether this event is mediated by phosphorylation-de-
pendent ubiquitination. Because Fbw7a promoted SRC-
3 degradation, and to aid in the detection of ubiquitinated
SRC-3, we changed the ratio of SRC-3 versus Fbw7a to
1:1 (as compared to 1:5 and 1:25 in Figure 4Cii). Our re-
sults showed that Fbw7a clearly enhanced ubiquitination
of the wild-type SRC-3 (Figure 4D, lanes 1 and 2) and
that this enhancement was attenuated or completely abol-
ished when either S505 (S505A) (lanes 3 and 4) or the
priming phosphorylation site S509 (S509A) was mutated
to alanine (lanes 5 and 6), respectively.
Interestingly, the molecular weights of the ubiquitinated
species suggested that SRC-3 was largely multi-(mono)-
ubiquitinated and not polyubiquitinated under our test
conditions (Figures 4Dand5GandFigureS1 in theSupple-
mental Data available with this article online). Since it is
accepted that ubiquitin/proteasome degradation requires
the formation of a ubiquitin chain of at least four ubiquitins
(polyubiquitination) on the same lysine of target proteins,
we tested whether Fbw7a also promotes eventual polyu-
biquitination of SRC-3. Indeed, despite the fact that multi-
(mono)ubiquitinationcomprises themajority formofSRC-3,
both multi-(mono)ubiquitination and polyubiquitination of
SRC-3 could be enhanced by Fbw7a in a dosage-depen-
dent manner (Figure 4E, lanes 1–3; note the ratios of
SRC-3 and Fbw7a [1:2 and 1:5] were within the lower
range [1:5] used in Figure 4C to aid in the detection of
ubiquitinated SRC-3). As a control, the ability of Fbw7a
to enhance SRC-3 ubiquitination required the F box of
Fbw7a, a region responsible for the recruitment of the
SCF complex; an F box deletionmutant (delF) was incapa-
ble of enhancing SRC-3 ubiquitination (Figure 4F).
We tested the effects of Fbw7a on the ubiquitination of
SRC-1 and SRC-2 family members. Despite being ubiqui-
tinated, the ubiquitination of SRC-1 and SRC-2 was not
enhanced by Fbw7a (Figure 4G, lanes 1–4, long and short
exposure), demonstrating an unexpected degree of spe-
cific ubiquitination enhancement by Fbw7a on SRC-3.
Since the critical regulatory element spanning S505–
S509 in SRC-3 was not present in the corresponding
regions of SRC-1 or SRC-2, we exchanged the corre-
sponding sequences in SRC-2 (515SPVGV519) with the se-
quences found on SRC-3 (505SPMAS509) (Figure 4Hi). The
exchange revealed that SRC-2/515SPMAS519 acquired theCell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc. 1129
Figure 4. Phosphorylation-Dependent Ubiquitination of SRC-3
(A) Protein extracts from HEK293 cells cotransfected with the indicated Flag-SRC-3 and HA-ubiquitin were immunoprecipitated with anti-Flag.
Ubiquitination of Flag-SRC-3 from the immunoprecipitates was examined by anti-HA. Afterward, the membrane was stripped and reprobed
with the following antibodies: anti-SRC-3, anti-Fbw7, and anti-Fbw1a and 1b (this antibody detected Fbw1 from total cell lysate, data not
shown). n.s., nonspecific; IgH, immunoglobulin heavy chain. The position of unmodified SRC-3 after alignment of the top two panels was
indicated.
(Bi) SRC-3protein levels from theFbw7knockdowncellsweredeterminedbyanti-SRC-3. Theb-actinwasusedas aprotein loading control. The values
below represented the relative intensity of Fbw7 and SRC-3 from control and specific siRNA-transfected cells. (Bii) To determine the effects of Fbw7a
on thehalf-life of SRC-3, Flag-SRC-3was cotransfectedwithmyc-Fbw7a intoHEK293 cells and treatedwith cycloheximide (20mg/ml) for the indicated
times.
(Ci)Wild-typeSRC-3 (GST-S/TS505) andmutant (GST-S/TS505A)werephosphorylatedbyGSK3 in vitrowhere indicated andused in aGSTpull-down
assay by incubatingwith radioactive Fbw7a. (Cii) The indicated Flag-SRC-3 (0.2 mg)was cotransfectedwith different amounts of Flag-Fbw7a (1 mg and
5 mg, respectively, as indicated by the ratios) intoHEK293cells. Increasedexpression of Flag-Fbw7awas verified by anti-Flag. Theb-actinwas usedas
a loading control.1130 Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc.
same ubiquitination characteristics as native SRC-3.
SRC-2/515SPMAS519 also showed increased phosphory-
lation of S515 (equivalent of S505 in SRC-3) to a similar ex-
tent as SRC-3 (Figure 4Hii, top panel, lanes 1–3). Impor-
tantly, ubiquitination of SRC-2/515SPMAS519 and not
wild-type SRC-2 was susceptible to enhancement by
Fbw7a (Figure 4I, lanes 2 and 4). Taken together, our re-
sults identify an SRC-3-specific degron element
(505SPMAS509) that is targeted by SCFFbw7a for ubiquitina-
tion in a phosphorylation-dependent manner.
Potential SRC-3 Ubiquitination Sites and SRC-3
Multi-(Mono)Ubiquitination
We next divided full-length SRC-3 into five regions
(Figure 5A) to determine where ubiquitination occurred.
We focused our attention on the RID and HAT regions,
as they contain functionally characterized motifs and
were more efficiently ubiquitinated (Figure 5B). We found
two and then one perfect sumoylation/ubiquitination con-
sensus sequences (fKXE: f, hydrophobic; K, lysine; X,
any amino acid; E, glutamic acid) within the RID and HAT
regions, respectively (Figure 5C) (Desterro et al., 1998;
Hoege et al., 2002). We mutated the lysine residue in
each of these three sites to arginine and noted that individ-
ual mutations of K723 or K786 to arginines significantly
reduced ubiquitination as compared to the wild-type
SRC-3 (Figure 5D, lanes 1–3); mutation of K1194 to argi-
nine did not affect SRC-3 ubiquitination (Figure 5D, lane 4).
To testwhether Fbw7a could directly ubiquitinate SRC-3,
an in vitro ubiquitination assay was performed. Mutation
of the two potential ubiquitination sites (K723 and K786)
to arginines significantly reduced SRC-3 ubiquitination
by Fbw7a (Figure 5Eiii, compare lanes 3 and 4 to 2). Inter-
estingly, mutation of S505 to alanine also reduced ubiqui-
tination of SRC-3 by Fbw7a (lane 5). Our results further
substantiate that phosphorylation of S505 is involved in
the regulation of SRC-3 ubiquitination and that K723 and
K786 represent the prime candidate sites for ubiquitina-
tion by Fbw7a.
To examine whether ubiquitination on K723 and K786 is
important for SRC-3 stability, we showed that Fbw7a re-
duced the levels of wild-type SRC-3 in a dosage-depen-
dent manner (Figure 5Fi, lanes 1–3; note that the ratiosused were the same as in Figure 4C). In contrast, the
K723R and K786R mutants demonstrated resistance to
degradation at both low and high concentrations of
Fbw7a (lanes 2, 3, 5, 6, 8, and 9). In support, our results
showed that the half-lives of K723R and K786R mutants
were substantially longer than the wild-type SRC-3
(Figure 5Fii).
We remained surprised that the majority of ubiquiti-
nated SRC-3 appeared to be predominantly multi-(mono)-
ubiquitinated and not polyubiquitinated in form (Figure S1;
Figures 4D and 4E). To substantiate that SRC-3 is indeed
multi-(mono)ubiquitinated, we showed that treatment with
the proteasome inhibitor MG132 resulted in an accumula-
tion of extensively polyubiquitinated SRC-3 that was
barely detectable in the absence of MG132 (Figure 5Gi,
lanes 1 and 2). The strikingly different SRC-3 ubiquitina-
tion pattern in the presence of MG132 suggested that
the phosphoactivated SRC-3 is mainly multi-(mono)ubi-
quitinated and that the polyubiquitinated forms are more
unstable and transient.
To unequivocally demonstrate that SRC-3 is multi-
(mono)ubiquitinated, we compared ubiquitination pat-
terns in the presence of wild-type ubiquitin or a ubiquitin
mutant molecule with all seven lysines mutated to argi-
nines (UbKO). Because this ubiquitin mutant (UbKO) lacks
all potential sites for polyubiquitination, the UbKO mole-
cule supports only multi-(mono)ubiquitination on SRC-3.
Importantly, the SRC-3 ubiquitination patterns formed in
the presence of the wild-type ubiquitin were found to be
representative of that formed with UbKO (Figure 5Gii,
lanes 1 and 2). This conclusion is further supported by tri-
ple antibody (anti-Flag, anti-HA, anti-SRC-3) purification
experiments (see Supplemental Experimental Procedures
and Figure S1 for details) where similar ubiquitination pat-
terns as that in (ii) were obtained (Figure 5Giii). In brief, two
tags were placed on different proteins, i.e., Flag tag on
SRC-3 and HA tag on ubiquitin, and the final purified prod-
ucts were detected by a third specific antibody to SRC-3.
Because the captured proteins after the first round of pu-
rification were released by heating at 95C, we conclude
that the detected bands are indeed modified by HA tag
containing Ub (HA-Ub-Flag-SRC-3) and are not simply
SRC-3-associated proteins. Taken together, our results(D) Protein extracts fromHEK293 cells cotransfectedwith the indicated Flag-SRC-3, HA-ubiquitin, andwith or withoutMyc-Fbw7a, were immunopre-
cipitated with anti-Flag. Ubiquitination of Flag-SRC-3 from the immunoprecipitates was examined by anti-HA. The position of unmodified SRC-3 after
alignment of top two panels was indicated.
(E) Same as in (D) except different ratios were used.
(F) Protein extracts fromHEK293 cells cotransfectedwith Flag-SRC-3, HA-ubiquitin, andwild-type Fbw7a or Fbw7awith deletion of the F box (Fbw7a
delF) were immunoprecipitated with anti-Flag. Ubiquitination of Flag-SRC-3 from the immunoprecipitates was examined by anti-HA. The position of
unmodified SRC-3 after alignment of top two panels was indicated.
(G) HEK293 cells were cotransfected with SRC-1, SRC-2, or SRC-3, HA-ubiquitin with or without Fbw7a, and followed by immunoprecipitation with
anti-Flag. Ubiquitination from the immunoprecipitates was examined by anti-HA.
(Hi) Schematic depiction of the critical element on SRC-3 (505SPMAS509) and its corresponding sequences on SRC-2. The 505SPMAS509 sequences
from SRC-3 were introduced into SRC-2 to generate SRC-2/SPMAS. (Hii) After introduction of the sequences, phosphorylation of the S515 (SRC-2/
SPMAS) was determined by anti-phospho-S505 (SRC-3).
(I) SRC-2 or SRC-2/SPMAS, HA-ubiquitin with or without Fbw7a were cotransfected into HEK293 cells and immunoprecipitated with anti-Flag. Ubiq-
uitination from the immunoprecipitates was examined by anti-HA. The levels of SRC-2, SRC-2/SPMAS, Fbw7a, and HA-Ub were determined by the
indicated antibodies.Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc. 1131
Figure 5. Identification of Potential SRC-3 Ubiquitination Sites
(A) Schematic representation of the five fragments derived from SRC-3. bHLH, basic-helix-loop-helix; S/T, serine/threonine; RID, receptor interaction
domain; CID, CBP/p300 interaction domain; HAT, histone acetyltransferase activity.
(B) HEK293 cells were cotransfected with the full-length SRC-3 or the indicated SRC-3 fragment and HA-ubiquitin and immunoprecipitated with anti-
Flag. Ubiquitination from the immunoprecipitates was examined by anti-HA (top panel).
(C) Sequence analysis showed that RID and HAT regions of SRC-3 each contain two and one consensus ubiquitination/sumoylation sites, respec-
tively.1132 Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc.
substantiate that although both multi-(mono)ubiquitina-
tion and polyubiquitination occur on SRC-3 (Figure 4E),
the predominant phosphorylation-dependent form of
SRC-3 is mainly multi-(mono)ubiquitinated.
Phosphorylation-Dependent Nonproteolytic
Activational Functions of SRC-3 Ubiquitination
The ubiquitin/proteasome pathway has been implicated in
transcriptional functions of nuclear receptors and their co-
activators, but the underlyingmechanisms are not defined
(Lonard et al., 2004). Since phosphorylation of SRC-3 at
S505 and S509 regulated the ubiquitination of SRC-3,
we addressed the functional importance of these two po-
tential ubiquitination sites, K723 and K786, for the tran-
scriptional activation capacity of SRC-3. Since K723 and
K786 reside in close proximity to the receptor interaction
motifs (LXXLL) of SRC-3 (Figure 6A), we first employed
coimmunoprecipitation to determine whether ubiquitina-
tion affects the ability of SRC-3 to interact with its pre-
ferred NR, ER, using SRC-3 mutants carrying individual
mutations to arginine at K723 (K723R), K786 (K786R), or
K1194 (K1194R). As expected, the binding between ER
andwild-type SRC-3was strongly induced by the addition
of the cognate ligand, estradiol (Figure 6B, top panel,
lanes 1 and 2). The ligand-induced interactions between
ER and the K723R or K786R SRC-3 mutants were mark-
edly reduced (Figure 6B, top panel, lanes 3–6), whereas
a control mutation at K1194 (K1194R) did not affect the
cellular interaction with ER (Figure 6B, top panel, lanes 7
and 8). Despite the fact that K723R and K786R SRC-3mu-
tants were defective in interacting with ER, these two mu-
tants interacted with CBP equally well, as did wild-type
SRC-3 (Co-IP) (Figure 6C, top two panels), indicating
that the observed defect in protein-protein interaction is
selective for ER.
Phosphorylation of S118 on ER is a site known to be re-
quired for efficient ER transcriptional activity, and the de-
gree of S118 phosphorylation induced by estradiol can
represent corroborative in vivo evidence of SRC-3 recruit-
ment and ER activity. We found that cellular phosphoryla-
tion of S118 on ER was reduced in the presence of K723R
and K786R SRC-3 mutants as compared to that induced
by wild-type and K1194R SRC-3 (Figure 6B, fourth panel
from top, lanes 2, 4, 6, and 8). This difference was not
due to altered SRC-3 subcellular localization since muta-tions did not alter the distribution of SRC-3 (Figure S2).
Our results indicate that ubiquitination at K723 and K786
are important for SRC-3 to efficiently interact with ER.
We next investigated whether Fbw7a is involved in ER
activation of transcription. Our results showed that
Fbw7a is a potent co-coactivator of ER activity in the pres-
ence of wild-type SRC-3 in a reporter assay (Figure 6Di,
columns 4 and 6). The potentiation of ER activity by
Fbw7a was decreased when K723 or K786 but not
K1194 were individually mutated to arginine (Figure 6Di,
columns 6, 8, 10, and 12). Fbw7a also functions as a co-
coactivator for AR, and ubiquitinations of K723 and
K786 are important for AR activity (Figure 6Dii). Impor-
tantly, the K723R and K786R SRC-3mutants also showed
a reduced activity in a reporter gene assay in the absence
of cotransfected Fbw7a (Figure S3) as well as a reduced
ability to induce the expression of an endogenous ER tar-
get gene (pS2) in response to estradiol as compared to the
wild-type SRC-3 and control mutant (K1194R) SRC-3
(Figure 6E, lanes 2, 4, 6, and 8).
To support the important roles of GSK3 and Fbw7a in
ER activation, we examined the effects of GSK3 and
Fbw7a knockdown on the induction of several endoge-
nous ER target genes, namely the pS2, c-Myc, and PR,
by estradiol. Knockdown of GSK3 or Fbw7 (Figure 6Fi) sig-
nificantly reduced the estradiol-iuduced expression of
pS2, c-Myc, and PR (ii, iii, and iv, respectively). Since
phosphorylation of S505 on SRC-3 is induced by estradiol
and phosphorylation of S505 is required for the binding
and ubiquitination of SRC-3 by Fbw7a, we investigated
the recruitment of Fbw7a to the promoters of pS2 and
PR by chromatin immunoprecipitation (ChIP) assays.
Our results showed that Fbw7a was specifically recruited
to the promoters of pS2 and PR (compare to the control
cyclophilin promoter) along with SRC-3 and ER in an es-
tradiol-dependent manner (Figure 6Gi); knockdown of
Fbw7 significantly reduced the recruitment of SRC-3
and ER (Figure 6Gii).
Ubiquitination Enhances the Transcriptional
Activity of SRC-3
To further substantiate the importance of SRC-3 ubiquiti-
nation in this NR-mediated transcriptional event, we found
that SRC-3 ubiquitination was enhanced by estradiol (and
a ligand for AR, R1881) (Figure 7Ai, top panel, lanes 1 and 2;(D) The indicated Flag-SRC-3 construct was cotransfected with HA-ubiquitin into HEK293 cells and immunoprecipitatedwith anti-Flag. Ubiquitination
of proteins from the immunoprecipitates was examined by anti-HA (top panel).
(Ei) Shown is the 6xHis-Fbw7a purified from sf9 cells. (Eii) Shown is the SRC-3 proteins purified from transfected HEK293 cells. (Eiii) In vitro ubiquiti-
nation of SRC-3 by Fbw7a was performed using the purified proteins shown in (Ei) and (Eii) reconstituted with purified E1, UbcH5, and ubiquitin.
(Fi) Experiments were performed as in Figure 4C, except K723R and K786R SRC-3 mutants were used. (Fii) HEK293 cells were transfected with the
expression constructs for the Flag-tagged wild-type, K723R, or K786R SRC-3. Western blotting with anti-Flag was performed on samples collected
after cycloheximide (20 mg/ml) treatment at the indicated time to determine the Flag-SRC-3 levels. The intensity at the beginning of cycloheximide
treatment (time 0) is set as 1 for each group.
(Gi) Protein extracts from HEK293 cells cotransfected with Flag-SRC-3 and HA-ubiquitin treated or not with proteasome inhibitor MG132 (20 mM) for
6 hr were immunoprecipitated with anti-Flag. Ubiquitination from the immunoprecipitates was examined by anti-HA. (Gii) Protein extracts from
HEK293 cells cotransfected with Flag-SRC-3 and wild-type HA-ubiquitin or HA-ubiquitin mutant (UbKO) were immunoprecipitated with anti-Flag
and analyzed as in (Gi). (Giii) As in (Gii) except the samples were purified according to the scheme. The purified samples were then analyzed by
anti-SRC-3 to ensure that the detected bands are indeed ubiquitinated SRC-3.Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc. 1133
Figure 6. A Phosphorylation-Dependent Ubiquitination Code that Regulates Diverse Functions of SRC-3
(A) Schematic representation of the LXXLL and fKXE motifs from the RID of SRC-3.
(B) The interactions of ER and each of the indicated SRC-3swere determined by a coimmunoprecipitation assay. HEK293 cells cotransfected with ER
and the indicated SRC-3 construct were treated or not with estradiol (108 M) for 1 hr and were immunoprecipitated with anti-ER followed by western
blotting with the indicated antibodies. The levels of estradiol-induced ER phosphorylation at Ser118 and the total levels of ER expression were per-
formed on the same lysate in a separate western blotting (bottom two panels).
(C) HEK293 cells were transfected with HA-tagged CBP and the indicated Flag-SRC-3 constructs to determine the interactions of CBP and each of
the indicated SRC-3s by a coimmunoprecipitation assay.
(Di) HeLa cells grown in phenol red-free medium (supplemented with 5% charcoal-stripped FBS) were transfected with an ER-responsive element/
luciferase reporter gene, expression plasmids for ER with or without SRC-3, and Fbw7a as indicated. Estradiol (108 M) was added to the transfected
cells 18 hr posttransfection and incubated for an additional 24 hr. Luciferase activity was determined and normalized to the amount of total input pro-
tein. (Dii) HeLa cells grown in phenol red-free medium (supplemented with 5% charcoal-stripped FBS) were transfected with an MMTV-luciferase1134 Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc.
Figure S4A); an SRC-3 mutant that did not interact with
ER (SRC-3 AAA) was devoid of estradiol-induced en-
hancement (Figure 7Ai, top panel, lanes 3 and 4). We
also found that this enhanced ubiquitination was selective
for ER, AR, and their respective ligands since PR and pro-
gesterone had no detectable effect on SRC-3 ubiquitina-
tion (Figure 7Ai and Figure S4B). Concomitant with in-
creased ubiquitination, increased S505 phosphorylation
was detected on the wild-type but not on the mutant
SRC-3 (Figure 7Ai, second panel from top). Importantly,
estradiol-enhanced ubiquitination of SRC-3 also was ob-
served on endogenous SRC-3 prepared fromMCF-7 cells
(Figure 7Aii), and it was mediated by Fbw7a and GSK3
since knockdown of Fbw7a or GSK3 abolished the estra-
diol-mediated induction of SRC-3 ubiquitination (Fig-
ure 7Aiii and iv, respectively; compare to Figure 7Aii, top
panel). Concomitant with the reduction of SRC-3 ubiquiti-
nation, we also found that knockdown of Fbw7a or GSK3
greatly reduced the estradiol-induced cellular interactions
between SRC-3 and ER (Co-IP) (Figure 7Aii, bottom panel,
3.7-fold versus iii and iv, bottom left panels, 1.3- and 1.8-
fold, respectively).
To demonstrate that the intrinsic transcriptional activity
of SRC-3 is affected byGSK3 and Fbw7a, we first showed
that only the wild-type GSK3, not the kinase-defective
mutant, enhanced the intrinsic transcriptional activity of
GAL4-SRC-3 in an S505 phosphorylation-dependent
manner (Figure 7Bi, compare columns 4–6 and 1–3). Fur-
thermore, only thewild-type Fbw7a, not the F box-deleted
mutant, enhances the activity of GAL4-SRC-3 in a dos-
age-dependent manner (Figure 7Bii). As expected,
GSK3 and Fbw7a synergistically enhanced the activity
of SRC-3 (Figure 7Biii), and mutation of phosphorylation
sites (S505, S505/509) and ubiquitination sites (K723
and K786 but not K1194) abolished the enhancement of
SRC-3 activity induced by Fbw7a (Figure S5). The results
suggest that phosphorylation-dependent ubiquitination of
SRC-3 confers a transcription activation function prior to
promoting SRC-3 degradation.
Because Fbw7a, similar to estradiol, increased not only
the multi-(mono)ubiquitination but also the polyubiquitina-
tion of SRC-3 (Figures 4E and 7A), we transfected thewild-
type ubiquitin molecule or a ubiquitin mutant with all seven
lysines mutated to arginines (UbKO) to distinguish the
functions of multi-(mono)ubiquitinated SRC-3 from thatof polyubiquitinated SRC-3. In this scenario, the wild-
type ubiquitin supports both multi-(mono)ubiquitination
and polyubiquitination of SRC-3, whereas UbKO supports
only multi-(mono)ubiquitination of SRC-3. Our results
showed that Fbw7a enhanced GAL4-SRC-3 activity in
the presence of wild-type ubiquitin as well as UbKO in
a dosage-dependent fashion (Figure 7Biv, compare col-
umns 4–6, 7–9, and 10–12). Interestingly, SRC-3 appears
even more active in the presence UbKO than in the pres-
ence of wild-type ubiquitin. Our results suggest that multi-
(mono)ubiquitination of SRC-3 is sufficient for achieving
its full potential as a coactivator. Because both multi-
(mono)ubiquitination and polyubiquitination occur on
SRC-3 under normal physiological conditions, we suggest
the possibility that transition from multi-(mono)ubiquitina-
tion (activation) to polyubiquitination (degradation) cou-
ples with transcriptional activation to control the ampli-
tude and lifetime of SRC-3 coactivator activity.
To substantiate that transition from multi-(mono)ubiqui-
tination to polyubiquitination of SRC-3 is coupled with the
transcriptional coactivation of ER, we determined the
ubiquitinated forms of SRC-3 in the presence or absence
of transcription. Bothmulti-(mono)ubiquitination and poly-
ubiqitination of SRC-3 were enhanced in the presence of
estradiol (Figure 7C, lanes 1 and 2). In marked contrast,
when active transcription was blocked by actinomycin
D, estradiol induced only the multi-(mono)ubiquitinated
form of SRC-3 (Figure 7C, lane 3). Notably, the protein in-
teractions between SRC-3 and ER induced by estradiol
were not affected by actinomycin D (Figure 7C, third and
fourth panels, lanes 1 and 3). In addition, we demonstrated
a more rapid turnover of SRC-3 when it is involved in tran-
scriptional activation (particularly during the first 2 hr after
addition of estradiol, Figure 7D, compare lanes 1 [100%],
2 [75%], and 6 [40%]); this rapid turnover of SRC-3was re-
tarded when transcription was prevented by actinomycin
D (Figure 7D, lanes 2 [75%], 6 [40%], and 10 [67%]), sug-
gesting that the transition from multi-(mono)ubiquitination
to polyubiquitination of SRC-3 is indeed coupled with
transcriptional progression.We next tested the ubiquitina-
tion of an SRC-3 mutant that is transcriptionally inactive
due to deletion of the region responsible for interaction
with CBP/p300. Unlike the wild-type SRC-3, neither phos-
phorylation of S505nor ubiquitination of this inactiveSRC-3
(delCID) can be induced by estradiol (Figure 7Ei, top tworeporter gene, expression plasmids for AR, wild-type or SRC-3 mutants, and with or without Fbw7a as indicated. Results were from three
independent experiments performed in duplicate. The error bars represent standard error of the mean.
(E) HeLa cells grown in phenol red-free medium (supplemented with 5% charcoal-stripped FBS) were transfected with ER and the indicated SRC-3
constructs. Estradiol (108 M) was added to the transfected cells 18 hr posttransfection as indicated and incubated for an additional 24 hr. The total
RNAs were prepared as described and used for RT-PCR to detect the induction of an endogenous ER target gene pS2. The levels of ER, Flag-SRC-3,
and GAPDH from the same samples were detected with specific primers and used as a loading control. Results of a representative from two inde-
pendent experiments with similar results were shown.
(Fi) Knockdown of GSK3 or Fbw7 in MCF-7 cells was achieved by transfection of specific siRNA and verified by Western blotting. (Fii–Fiv) The total
RNA from the GSK3 or Fbw7 knockdown cells in (Fi) was analyzed for the expression of ER target genes by semiquantitated RT-PCR (pS2, [Fii]) or by
quantitative PCR (c-Myc, [Fiii]; and PR, [Fiv]). The numbers are the relative average levels from two independent experiments.
(Gi) Chromatin immunoprecipitation (ChIP) assay demonstrated that recruitment of ER, SRC-3, and Fbw7 to the promoter regions of pS2 and PR is
specific and estradiol dependent. Cyclophilin promoter is used as a control. (Gii) After knockdown of Fbw7, the recruitment of SRC-3, ER, and Fbw7 to
the pS2 and PR promoters was analyzed by ChIP as in (Gi).Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc. 1135
Figure 7. Multi-(Mono)Ubiquitinated SRC-3 Is Sufficient to Recruit Active Transcription Machinery
(Ai) HEK293 cells were cotransfected with wild-type or SRC-3 mutant, ER, and HA-Ub, treated or not with estradiol (108 M) for 1 hr when indicated
and prepared for immunoprecipitation with anti-Flag. Ubiquitination of SRC-3 in the immunoprecipitates was examined by anti-HA. The SRC-3 (AAA)
mutant that failed to interact with ER has been demonstrated and described earlier (Zheng et al., 2005). (Aii) For the detection of ubiquitinated forms of
endogenous SRC-3 from MCF-7 cells, the cells were lysed using the modified RIPA buffer following treatment with estradiol (108 M) for 1 hr. The
lysate was immunoprecipitated with antibodies against SRC-3 (Wu et al., 2002), processed as described above, and analyzed by Ub antibodies.1136 Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc.
panels, compare lanes 2 and 4). In contrast to the wild-
type SRC-3 (Figure 7D), the half-life of this mutant is not
altered in the presence of estradiol (Figure 7Eii).
To provide additional substantiation that multi-(mono)-
ubiquitinated SRC-3 is sufficient for its initial intracellular
recruitment by ER, we performed Co-IP experiments from
cells exposed to either wild-type ubiquitin or UbKO. The
coimmunoprecipitated SRC-3 was then run on SDS-
PAGE optimized for the separation of SRC-3 with different
mobilities. The slower-migrating SRC-3 is enriched in both
the presence of wild-type ubiquitin or UbKO (Figure 7F,
compare lanes 2, 4, and 5), indicating again that the
multi-(mono)ubiquitinated SRC-3 is sufficient for interac-
tion with ER.
Since SRC-3 is essential for recruitment of RNA Pol II
and transcriptional activation of ER target genes (Shao
et al., 2004), we performed crosslinking experiments to
determine Pol II recruitment and to firmly demonstrate
that multi-(mono)ubiquitinated SRC-3 is sufficient to sup-
port transcriptional activation by ER (Schmitt-Ulms et al.,
2001). To ensure that SRC-3 is exclusively multi-(mono)-
ubiquitinated, UbKO was used. As expected, multi-(mono)ubiquitination of SRC-3 is enhanced by estradiol
in the presence of UbKO (Figure 7Gi). Next, we cross-
linked cells with formaldehyde following treatment with
estradiol and then protein extracts were subjected to
two rounds of immunoprecipitation (IP). The crosslinked
immunoprecipitates from the first round IP with ER anti-
bodies were crosslink-reversed and used for reimmuno-
precipitation with Pol II antibodies followed by western
blotting to detect phosphorylation on Pol II CTD. Our re-
sults showed thatmulti-(mono)ubiquitinated SRC-3 is able
to recruit Pol II phosphorylated at both Ser5 and Ser2 of
the CTD (Figure 7Gii). Since phosphorylation of Ser5 oc-
curs during transcription initiation and phosphorylation
of Ser2 is enriched toward the 30 end of the gene during
transcription, our results indicate that multi-(mono)ubiqui-
tinated SRC-3 is capable of recruiting active transcription
machinery.
Finally, to directly prove that multi-(mono)ubiquitinated
SRC-3 is active in transcription, we compared the activi-
ties of precise quantities of purified multi-(mono)ubiquiti-
nated and nonubiquitinated SRC-3 (Figure 7Hi and legend
for details) in a chromatin-based in vitro transcriptionThe immunoprecipitated SRC-3 and the coimmunoprecipitated ER levels were detected by anti-SRC-3 and anti-ER, respectively. The numbers in-
dicated the relative intensity of coimmunoprecipitated ER in the presence or absence of estradiol. The ligand-independent interaction was set as 1.
(Aiii) Knockdown of endogenous Fbw7a in MCF-7 was performed as described earlier. The ubiquitination of SRC-3 from the Fbw7 knockdown sam-
ples were processed, analyzed and presented as in (Aii). (Aiv) Knockdown of endogenous GSK3 in MCF-7 was performed as described earlier. The
ubiquitination of SRC-3 from the GSK3 knockdown samples were processed, analyzed, and presented as in (Aii).
(Bi) HeLa cells were transfected with aGAL4-responsive element/luciferase reporter gene, GAL4DBD-SRC-3 (WT) or GAL4DBD-SRC-3 (S505A), and
wild-type or kinase-dead GSK3. Luciferase activity was determined and normalized to the amount of total input protein. (Bii) HeLa cells were trans-
fected with a GAL4-responsive element/luciferase reporter gene, GAL4 DBD-SRC-3, and increasing concentrations of Fbw7a or Fbw7adelF. Empty
vector was added to make total amounts of input plasmids equal. Luciferase activity was analyzed as in (Bi). (Biii) The luciferase activity from HeLa
cells transfected with GSK3, Fbw7a alone, or GSK3, Fbw7a combined were analyzed as in (Bi). (Biv) As in (Bii), except expression vector for either the
wild-type ubiquitin or the ubiquitn mutant (UbKO) was cotransfected. Luciferase activity was analyzed as in (Bi). Comparable levels of SRC-3 were
shown. The error bars represent standard error of the mean.
All results were from three independent experiments performed in duplicate.
(C) HEK293 cells were cotransfected with SRC-3, ER, and HA-Ub, treated or not with estradiol (108 M) for 1 hr when indicated, and prepared for
immunoprecipitation with anti-Flag. Actinomycin D (5 mg/ml) was added 1 hr prior to the addition of estradiol when indicated. Ubiquitination of
SRC-3 in the immunoprecipitates was examined by anti-HA. The position of unmodified SRC-3 after alignment of top two panels was indicated.
(D) The half-lives of SRC-3 from (C) were determined. Shown is a representative from three independent cycloheximide chase experiments with sim-
ilar results. The quantification of these experiments was shown in the graph. The error bars represent standard error of the mean.
(Ei) Protein extracts fromHEK293 cells transfected with wild-type SRC-3 ormutant SRC-3 (delCID), treated or not with estradiol (108M) for 1 hr when
indicated were analyzed for the ubiquitination and phosphorylation of SRC-3 as described earlier. (Eii) The half-lives of SRC-3 mutants (delCID) from
(Ei) were determined. Shown is a representative from three independent cycloheximide chase experiments with similar results. The quantification of
these experiments was shown in the graph. The error bars represent standard error of the mean.
(F) Protein extracts from HEK293 cells cotransfected with SRC-3, ER, wild-type HA-Ub, or HA-UbKO, treated or not with estradiol (108 M) for 1 hr
when indicated were prepared for immunoprecipitation. The immunoprecipitated ERwas revealed by anti-ER, and the coimmunoprecipitated SRC-3
was resolved on a 6% SDS-PAGE optimized for separation of SRC-3 with different mobility and immunoblotted with anti-FLAG. The input lane rep-
resents 10% of the protein amount used for Co-IP.
(Gi) Protein extracts from HEK293 cells transfected with ER, SRC-3, and HA-UbKO were used to determine the effects of estradiol (108 M, 1 hr) on
SRC-3 ubiquitination. Ubiquitination of SRC-3 was determined as described previously. (Gii) As in (Gi), except the cells were crosslinked with form-
aldehyde (1%) prior to preparation of protein extracts. Immunoprecipitation was first carried out with ER antibodies, and the immunoprecipitates were
subject to crosslink reversal and then used for second immunoprecipitations with Pol II antibodies. The pellets and the supernatant from the second
immunoprecipitation were immunoblotted with the indicated antibodies. The numbers indicated the relative intensity of coimmunoprecipitated Pol II
phosphorylated at the indicated amino acids of CTD in the presence or absence of estradiol. The value in the absence of estradiol was set as 1.
(Hi) The multi-(mono)ubiquitinated SRC-3 was purified from HEK293 cells cotransfected with Flag-SRC-3 and HA-UbKO, and the nonubiquitinated
SRC-3 was purified from cells transfected with Flag-SRC-3. Similar amounts of purified multi-(mono)ubiquitinated and nonubiquitinated SRC-3 were
shown. (Hii) Chromatin-based in vitro transcription assay was performed as previously described (Feng et al., 2006). The error bars represent stan-
dard error of the mean.
(Ii) Protein extracts from HEK293 cells transfected with ER and HA-ubiquitin were used to determine the effects of estradiol (108 M, 1 hr) on ER ubiq-
uitination. (Iii) Protein extracts from HEK293 cells transfected with ER, HA-ubiquitin, with or without Fbw7a were used to determine the effects of
Fbw7a on ER ubiquitination.
(J) A phosphorylation-dependent ubiquitin clock regulates the transcriptional activation and lifetime of SRC-3.Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc. 1137
assay. Our results showed that multi-(mono)ubiquitinated
SRC-3 is transcriptionally more active with ER than its
nonubiquitinated counterpart (Figure 7Hii). Since estradiol
and Fbw7a enhanced the ubiquitination of SRC-3 (Figures
4D and 7C) but not ER (Figure 7I), our combined results in-
dicate that multi-(mono)ubiquitination promotes SRC-3
binding to ER and enhances its transcriptional function;
continued transcriptional activity then promotes the tran-
sition from multi-(mono)ubiquitination to polyubiquitina-
tion and eventual degradation of SRC-3.
DISCUSSION
In this report, we identified GSK3 as a kinase that phos-
phorylates SRC-3 on S505 and demonstrated that this
phosphorylation modulates SRC-3 transcriptional func-
tion and turnover. SRC-3 contains a motif (phosphode-
gron) in the S505–S509 region (Figure 3C), which targets
SRC-3 for degradation by the ubiquitin-dependent pro-
teasome pathway in a manner that is dependent on phos-
phorylation of S505 and S509 (Figure 4Cii). Signaling
through the Akt/PKB-GSK3 pathway affected SRC-3 by
phosphorylation of S505. Knockdown of GSK3 extended
the half-life of SRC-3 and resulted in elevated endogenous
SRC-3 levels in MCF-7 cells (Figure 3A). Overexpression
of wild-type GSK3 but not kinase-defective GSK3 (KD)
promoted ubiquitination of SRC-3 (Figure 3D), indicating
that both the kinase activity of GSK3 and phosphorylation
of S505 in SRC-3 are required.
SCFFbw7a Is an SRC-3-Selective E3 Ligase
We identified SCFFbw7a as an E3 ligase that binds to
SRC-3 in an S505 phosphorylation-dependent manner
(Figure 4Ci) and that is responsible for the further ubiquiti-
nation of SRC-3 (Figure 4A). To substantiate the role of
SCFFbw7a, we showed that knockdown of SCFFbw7a in-
creased SRC-3 cellular levels (Figure 4Bi) and overexpres-
sion of Fbw7a significantly reduced the half-life of SRC-3
(Figure 4Bii). Furthermore, only the wild-type, not the
mutant Fbw7a containing a deletion of the critical F box
sequence (Fbw7adelF), promoted ubiquitination (Fig-
ure 4F) and activation of SRC-3 (Figure 7Bii). Interestingly,
SCFFbw7a selectively enhanced ubiquitination of SRC-3
and not that of the homologous SRC-1 and SRC-2 family
members (Figure 4G). Sequence analysis revealed that
neither SRC-1 nor SRC-2 contains the specific degron/ac-
tron consensus element (505SPMAS509) that we identified
within SRC-3.
Discovery of a Proteolysis-Independent Role for
SRC-3 Ubiquitination in Its Coactivational Function
One of themost interesting aspects of this study is the dis-
covery of an unexpected enhanced transcriptional coacti-
vation function for SRC-3 that is determined by (mono)-
ubiquitination of SRC-3 within its receptor interaction
domain (RID) (Figure 5B) at K723 and K786 (Figures 5C–
5E). Fbw7a directly ubiquitinates SRC-3 at K723 and
K786 in an S505 phosphorylation-dependent manner1138 Cell 129, 1125–1140, June 15, 2007 ª2007 Elsevier Inc.(Figure 5E). These two ubiquitination sites are located in
close proximity to the LXXLL motifs responsible for the
binding to nuclear receptors, and mutation of SRC-3
K723 and K786 to arginines dramatically reduced the li-
gand-induced interaction with estrogen receptor (ER)
(Figure 6B). Concomitantly, phosphorylation of S118 on
ER, a critical site-specific hallmark for ER activation, was
diminished in K723R or K786R as compared to K1194R
or wild-type SRC-3. The importance of ubiquitination of
SRC-3 for its coactivation activity is supported by the abil-
ity of Fbw7a to further enhance the ability of the wild-type
SRC-3 but not the K723R or K786R SRC-3 mutants to
coactivate ER-regulated reporter and endogenous genes
(Figure 6E).
Knockdown of GSK3 and Fbw7a abolished the ubiqui-
tination of SRC-3 and abolished the interaction between
ER and SRC-3 and the induction of several ER target
genes by estradiol (Figures 7A and 6F). Accordingly, we
demonstrated that Fbw7a was recruited to the promoter
regions of ER target genes along with SRC-3 and ER in
an estradiol-dependent fashion; knockdown of Fbw7 sig-
nificantly reduced recruitment of SRC-3 and ER (Fig-
ure 6G). Our results substantiate that S505 phosphoryla-
tion-dependent ubiquitination of SRC-3 on K723 and
K786 by Fbw7a is critical for SRC-3 coactivation of ER-
dependent genes and that this region also acts as an
‘‘actron.’’
A Phosphorylation-Dependent Ubiquitination Code
Regulates SRC-3 Transcriptional Function
and Transcription-Factor Specificity
Since SRC-3 can function as a coactivator for a variety of
transcription factors, regulation of activity and specificity
toward different transcription factors is an issue of critical
importance. Phosphorylation-dependent ubiquitination, in
addition to modulating cellular SRC-3 turnover, regulates
SRC-3 coactivational activity and transcription factor
specificity. In context with ER, estradiol induces rapid
phosphorylation of SRC-3 and assembly into a complex
containing other coactivators with enhanced potential
for transcriptional activation (Wu et al., 2004). Our present
results indicate that a coordinated estradiol-mediated in-
crease in site-specific phosphorylation leads to multi-
(mono)ubiquitination and activation of SRC-3 (Figures
7A, 7E, and 7H), followed by enhanced SRC-3 binding to
ER, ER phosphorylation (Figure 6B), and efficient estra-
diol-mediated gene expression (Figure 6F).
A Ubiquitin Clock Regulates the Transcriptional
Lifetime of SRC-3
When the multi-(mono)ubiquitinated chain is extended on
SRC-3 during the course of transcription, it is generally ac-
cepted that the molecule will be degraded by the protea-
some when the polyubiquitin chain reaches 4–5+ addi-
tions of ubiquitin (Varshavsky, 2005). This interpretation
is substantiatedby the followingobservations: (1) theproc-
essivity of multi-(mono)Ub SRC-3 to poly-Ub SRC-3 is in-
hibited by interrupting transcription with actinomycin D
(Figure 7C); (2) in contrast to thewild-typeSRC-3, theS505
phosphorylation-dependent ubiquitination and estradiol-
induced degradation are lost on a transcriptionally inactive
SRC-3mutant (delCID) (Figures 7D and 7E); and (3) mono-
ubiquitinated SRC-3 is transcriptionally more active than
its nonubiquitinated counterpart in a direct chromatin-
based transcription assay (Figure 7H). By this scenario,
multi-(mono)ubiquitination plays both a transcriptional ac-
tivation role and also initiates a process that ultimately re-
sults in turnover of SRC-3 when it reaches a time-depen-
dent later stage of polyubiquitination in the presence of
estradiol. In this way, the ubiquitination region of SRC-3
acts as both an ‘‘actron’’ and a ‘‘degron.’’ Since ubiquitina-
tion depends on the prior phosphorylation of SRC-3, our
results confirm the importance of an inherent SRC-3 phos-
phorylation code and now include ubiquitination of SRC-3
as a critical element of this transcriptional code (Wu et al.,
2002, 2004).
It was reported previously that proteasomal degradation
of ER and coactivators is required for continuous efficient
transactivation by ER (Lonard et al., 2000). Our current re-
sults suggest that ubiquitination of SRC-3 is a biphasic
event and that transition from multi-(mono)ubiquitination
to eventual polyubiquitination is coupled to transcriptional
progression in the presence of ER (and AR). Since multi-
(mono)ubiquitination of SRC-3 is sufficient for its initial re-
cruitment by ER (Figure 7C) and for RNA Pol II recruitment
(Figure 7G), as well as for the subsequent polyubiquitina-
tion and degradation of SRC-3 (Figures 7D and 7E), an in-
creased local concentration or activity of Fbw7aby recruit-
ment onto promoters by SRC-3 (Figure 6G) could both
promote transcription and allow clearance of the promoter
in preparation for subsequent rounds of nascent cofactor
recruitment and transcriptional initiation. Our results indi-
cate that in response to select physiologic stimuli, phos-
phorylation-dependent ubiquitination regulates both the
function and relative transcriptional specificity of SRC-3.
This posttranslational code of modifications serves as
a ‘‘transcriptional time clock’’ that determines the func-
tional lifetime of the coactivator.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
HeLa, MCF-7, and HEK293 cells were obtained from ATCC and main-
tained in DMEM supplemented with 5% FBS. Charcoal-dextran strip-
ped serum was from Gemini. Estradiol, actinomycin D, cycloheximide,
and LiCl were from Sigma (St. Louis, MO); TNFa (Roche) was resus-
pended in PBS. Kinase inhibitors PD98059 (Promega) and LY294002
(Promega) were dissolved in DMSO. Puromycin was obtained from
Sigma and G418 was from Invitrogen. Wnt-3a was purchased from
R&D System and resuspended in PBS. Antibodies were from various
sources, including Sigma (anti-Flag and anti-b-actin), Cell Signaling
(anti-GSK3, anti-pS9-GSK3b, and anti-pS118-ER), Invitrogen (anti-
Fbw7, anti-Fbw1a, and Fbw1b), Santa Cruz (anti-ER, anti-HA, anti-
RNA polymerase II, and anti-Ub), Upstate (anti-GAL4), Covance
(anti-pSer2: H5 and anti-pSer5: H14), and Roche (anti-Myc and
anti-HA). The antibodies against SRC-3 and the phospho-specific
antibodies had been described previously (Wu et al., 2004). The
SMARTpool siRNA against GSK3 and Fbw7 were purchased fromDharmacon. Oligonucleotides were synthesized by Invitrogen, and
all sequences are available upon request.
Transfection and Luciferase Reporter Gene Assay
Transfection of plasmids was performed using Lipofectamine reagent
(Invitrogen) according to the manufacturer’s instruction. For treatment
of estradiol in reporter gene assay, estradiol (108 M) was added to
cells 24 hr posttransfection for another 24 hr, and TNFa was added
for 6 hr at 48 hr posttransfection. Cells were harvested and luciferase
activity was determined and normalized against total input protein. For
coimmunoprecipitation, estradiol was added for 1 hr before the cells
were harvested and lysed to prepare whole-cell extract.
Chromatin Immunoprecipitation Assay
ChIP assay was performed using the ChIP assay kit (Upstate). The
primer sequences had been previously described (Li et al., 2006; Yi
et al., 2005).
GST Pull-Down Assay and In Vitro Phosphorylation of SRC-3
GST fusion proteins were expressed in Bl21-Codon Plus cells (Strata-
gen), purified with glutathione beads, and used for GST pull-down as-
say. GST pull-down assay and in vitro phosphorylation of SRC-3 were
performed as previously described (Wu et al., 2004).
Recombinant Proteins
Recombinant ERa, Fbw7a, and SRC-3 proteins were generated by the
Bac-to-Bac baculoviral system (Invitrogen) and infection of Sf9 cells
grown in Grace’s medium supplemented with 10% fetal calf serum.
The proteins were purified by the Ni-nitrilotriacetic acid column
(QIAGEN).
In Vitro Ubiquitination Assay
In vitro ubiquitination assay was performed as previously described
(Koepp et al., 2001). The E1 enzyme, UbcH5, and ubiquitin were pur-
chased from Boston Biochem.
Quantitative PCR Analysis
MCF-7 cell total RNA was isolated from six-well culture dishes using
the RNeasy kit (QIAGEN). The mRNA for PR-B and c-Myc in MCF-7
cells was quantitated by Taqman-based reverse transcriptase-PCR
(RT-PCR) using the ABI Prism 7700 Sequence Detection System (Ap-
plied Biosystems). Primer sequences are available upon request.
All mRNA quantities are normalized against 18S RNA using Taqman
Ribosomal RNA Control Reagents.
Repetitions of Experiments
Experiments in all figures were repeated at least three times each.
Supplemental Data
The Supplemental Data for this article, including Supplemental Exper-
imental Procedures and Figures, can be found online at http://www.
cell.com/cgi/content/full/129/6/1125/DC1/.
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